Laboratory Corporation of America Holdings (NYSE:LH) has seen a mix of highs and lows in their recent market performance. American International Group Inc. and Vanguard Group Inc. have sold their shares in the company, while Goldman Sachs Group Inc., Compass Wealth Management LLC, Czech National Bank and others have increased their holdings. LH reported mixed Q4 results for 2023, with solid Q1 2024 earnings, beating revenue expectations but lagging in EPS. Despite this, LH's valuation has been questioned, with some considering the company potentially undervalued. Notably, five-year investors of LH are experiencing 67% ROI. The company declared a quarterly dividend of $0.72, engaging in multiple deals and acquisitions. For instance, it won a bid for select assets of Invitae, acquired assets of BioReference Health's Diagnostics, and announced the sale of select assets to OPKO Health. Additionally, LH launched Global Trial Connect to accelerate clinical trials and introduced a portfolio for weight management. With mixed performance and proactive business development, LH maintains investor interest.
Laboratory Corporation of America Holdings LH News Analytics from Mon, 03 Jul 2023 07:00:00 GMT to Sun, 23 Jun 2024 09:14:32 GMT -
Rating 0.5
- Innovation -3
- Information 7
- Rumor -6
